BMC Med:肾髓质肾素受体降低AngⅡ介导的高血压

2015-11-20 MedSci MedSci原创

中山大学医学院高血压研究所Fei Wang和同事研究发现肾髓质肾素受体通过激活局部肾素-血管紧张素系统降低大鼠血管紧张素Ⅱ介导的高血压。研究结果2015年11月10日于BMC Medicine在线发表。

中山大学医学院高血压研究所Fei Wang和同事研究发现肾髓质肾素受体通过激活局部肾素-血管紧张素系统降低大鼠血管紧张素Ⅱ介导的高血压。研究结果2015年11月10日于BMC Medicine在线发表。

背景:PRR(Pro-renin receptor,Pro-肾素受体 )是肾素-血管紧张素系统的一个新的组成部分,体外试验证实PRR调节肾素活性。PRR在肾脏肾髓质中高度表达,并且由AngⅡ(血管紧张素Ⅱ)介导。本研究的目的是测试肾髓质中表达的PRR 对AngⅡ介导的高血压中的可能的作用。

方法:建立大鼠AngⅡ灌注模型,动物模型制作方法:AngⅡ持续灌注,100 ng/kg/min。试验组随后在肾髓质内注射PRR特异性抑制剂PRO20,控制组随后静脉输注PRO20。使用植入式遥测系统连续一周测量大鼠平均动脉压。随后进行体内试验或体外试验进一步分析大鼠肾损伤、炎症、生化指标和蛋白质表达定位。

结果:植入式遥测系统证实AngⅡ灌注大鼠试验前平均动脉压基线为108 ± 5.8mmHg,AngⅡ灌注后平均动脉压升高164.7 ± 6.2 mmHg。随后试验组肾髓质注射PRO20,平均动脉压下降到128.6±5.8mmHg (P < 0.05),控制组随后静脉注入PRO20,平均动脉压仅有轻微变化。

试验组体内试验和体外试验进一步分析发现大鼠肾损伤相关指标(包括蛋白尿、肾小球硬化症和间质纤维化、炎症)、肾髓质和输尿管肾素活性都显著减弱。持续一周输注AngⅡ后,进一步分析发现大鼠血管平滑肌细胞中PRR的免疫反应性增加。

体外试验培养大鼠血管平滑肌细胞,研究发现AngⅡ也可介导可溶性PRR和肾素活性表现出类似的增量,而PRR抑制剂PRO20可显著降低肾素活性。

结论:大鼠肾髓质肾素受体通过放大肾髓质局部肾素反应降低AngⅡ引起的高血压。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=198013, encodeId=0c33198013f5, content=转化医学!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4D3YwOicNvmKe4SFfice8XbYUeaXKmPywR8IyYoO4s37MFHKiaicopGGjoicc3xicLul5jW1Oic3AMviacjg/0, createdBy=3ce42058518, createdName=皇家骑士团团尾, createdTime=Sun May 14 13:59:53 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773126, encodeId=7ff61e73126da, content=<a href='/topic/show?id=519c251e53' target=_blank style='color:#2F92EE;'>#AngⅡ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2517, encryptionId=519c251e53, topicName=AngⅡ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f1338488696, createdName=yyj075, createdTime=Sun Mar 13 22:42:00 CST 2016, time=2016-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974636, encodeId=9f2c19e463661, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Nov 27 19:42:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606719, encodeId=e8a01606e192d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 22 01:42:00 CST 2015, time=2015-11-22, status=1, ipAttribution=)]
    2017-05-14 皇家骑士团团尾

    转化医学!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=198013, encodeId=0c33198013f5, content=转化医学!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4D3YwOicNvmKe4SFfice8XbYUeaXKmPywR8IyYoO4s37MFHKiaicopGGjoicc3xicLul5jW1Oic3AMviacjg/0, createdBy=3ce42058518, createdName=皇家骑士团团尾, createdTime=Sun May 14 13:59:53 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773126, encodeId=7ff61e73126da, content=<a href='/topic/show?id=519c251e53' target=_blank style='color:#2F92EE;'>#AngⅡ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2517, encryptionId=519c251e53, topicName=AngⅡ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f1338488696, createdName=yyj075, createdTime=Sun Mar 13 22:42:00 CST 2016, time=2016-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974636, encodeId=9f2c19e463661, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Nov 27 19:42:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606719, encodeId=e8a01606e192d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 22 01:42:00 CST 2015, time=2015-11-22, status=1, ipAttribution=)]
    2016-03-13 yyj075
  3. [GetPortalCommentsPageByObjectIdResponse(id=198013, encodeId=0c33198013f5, content=转化医学!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4D3YwOicNvmKe4SFfice8XbYUeaXKmPywR8IyYoO4s37MFHKiaicopGGjoicc3xicLul5jW1Oic3AMviacjg/0, createdBy=3ce42058518, createdName=皇家骑士团团尾, createdTime=Sun May 14 13:59:53 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773126, encodeId=7ff61e73126da, content=<a href='/topic/show?id=519c251e53' target=_blank style='color:#2F92EE;'>#AngⅡ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2517, encryptionId=519c251e53, topicName=AngⅡ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f1338488696, createdName=yyj075, createdTime=Sun Mar 13 22:42:00 CST 2016, time=2016-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974636, encodeId=9f2c19e463661, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Nov 27 19:42:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606719, encodeId=e8a01606e192d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 22 01:42:00 CST 2015, time=2015-11-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=198013, encodeId=0c33198013f5, content=转化医学!, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo4D3YwOicNvmKe4SFfice8XbYUeaXKmPywR8IyYoO4s37MFHKiaicopGGjoicc3xicLul5jW1Oic3AMviacjg/0, createdBy=3ce42058518, createdName=皇家骑士团团尾, createdTime=Sun May 14 13:59:53 CST 2017, time=2017-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773126, encodeId=7ff61e73126da, content=<a href='/topic/show?id=519c251e53' target=_blank style='color:#2F92EE;'>#AngⅡ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2517, encryptionId=519c251e53, topicName=AngⅡ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f1338488696, createdName=yyj075, createdTime=Sun Mar 13 22:42:00 CST 2016, time=2016-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974636, encodeId=9f2c19e463661, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Fri Nov 27 19:42:00 CST 2015, time=2015-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606719, encodeId=e8a01606e192d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Nov 22 01:42:00 CST 2015, time=2015-11-22, status=1, ipAttribution=)]